Physician profile
Andrew W Murphy
NPI 1700970993
$5,531.62
in general payments reported to CMS, 2019-2025
22 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what 77% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $71.22 · 2021: $16.60 · 2023: $919 · 2024: $1,381 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.36 |
| Education | $312.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,166.13 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Biocryst US Sales Co., LLC | $806.10 | 2024-2025 | Orladeyo |
| Csl Behring | $488.82 | 2024-2025 | Andembry, Haegarda, Hizentra |
| Regeneron Healthcare Solutions, INC. | $447.97 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $372.45 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $324.44 | 2019-2025 | |
| Pharming Healthcare, INC. | $322.26 | 2019-2025 | Ruconest |
| Grifols USA, LLC | $276.62 | 2024-2025 | Xembify, Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $226.80 | 2023-2025 | Takhzyro, Cuvitru |
| Medtronic, INC. | $199.02 | 2023 | |
| Optinose US, INC. | $197.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $144.33 | 2024-2025 | Nucala |
| Abbott Laboratories | $142.79 | 2023 | Xact |
| Genzyme Corporation | $109.34 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.01 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $53.33 | 2025 | Neffy |
| Pfizer INC. | $36.75 | 2025 | |
| Ionis Pharmaceuticals, INC. | $35.78 | 2025 | |
| Amgen INC. | $23.14 | 2025 | Tezspire |
| Azurity Pharmaceuticals, INC. | $23.12 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $22.58 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $17.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.